Blogger's Note/Opinion: this current Cochrane Collaboration review does not add anything new to what is currently known except to say the deficits in ovarian cancer research/knowledge remain
~~~~~~~~~~~~~~~~
AbstractSaturday, March 02, 2013
2013 Cochrane Review: Surgical cytoreduction for recurrent epithelial ovarian cancer (including plain language summary eg. consumer/patient version)
Blogger's Note/Opinion: this current Cochrane Collaboration review does not add anything new to what is currently known except to say the deficits in ovarian cancer research/knowledge remain
open access: Resistance to PARP-Inhibitors in Cancer Therapy | Frontiers in Pharmacology of Anti-Cancer Drugs
Article
" There are 18 members of the PARP family of
proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage;
hence DNA damage-responsive PARPs are the most
likely mediators of PARPi effect......"
Friday, March 01, 2013
Suspected Extracolonic Neoplasms Detected on CT Colonography: Literature Review and Possible Outcomes
Abstract:
Rationale and Objectives
This
study summarizes the literature on the detection of cancer among
indeterminate extracolonic findings on computed tomographic (CT)
colonography in five targeted organs.
Materials and Methods
We
searched PubMed for English-language literature published between
January 1, 1994, and December 31, 2010. We describe extracolonic
findings in the kidney, lung, liver, pancreas, and ovary suspect for
malignancy as they are associated with high mortality. For each organ,
we calculated the median prevalence, positive predictive value (PPV),
and false positive rate of malignancy and a pooled false-positive rate
across studies.
Ureteroscopic management of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (MSH2)
abstract:
Objectives
- To report our experience with ureteroscopic laser ablation of upper tract urothelial carcinoma (UTUC) in patients with Lynch Syndrome (LS), as defined by a documented germline mutation in the MSH-2 gene.
- To increase awareness among urologists about UTUC in this unique patient population and refer to genetic counselling when appropriate.
Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer
Abstract:
J Altern Complement Med. 2013 Feb 27. [Epub ahead of print]
Source
1 Molecular Diagnostics Program, Fred Hutchinson Cancer Research Center , Seattle, Washington.Abstract
Objective:
Some ingestible complementary and alternative medicine (CAM) supplements, including herbal remedies, teas, and vitamins, have biological activities that make them likely to interact poorly with conventional chemotherapeutic treatments. This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together.
Methods:
A total of 219 patients with ovarian cancer who received care from 1 of 2 participating conventional oncology practices were surveyed about CAM use during and after ovarian cancer treatment.
Some ingestible complementary and alternative medicine (CAM) supplements, including herbal remedies, teas, and vitamins, have biological activities that make them likely to interact poorly with conventional chemotherapeutic treatments. This study surveyed women with ovarian cancer to document the extent to which women use ingestible CAM supplements and conventional chemotherapeutic treatments that are believed to be of potential concern when used together.
Methods:
A total of 219 patients with ovarian cancer who received care from 1 of 2 participating conventional oncology practices were surveyed about CAM use during and after ovarian cancer treatment.
Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer - Full Text View - ClinicalTrials.gov
trial details:
This study is not yet open for participant recruitment.
Verified February 2013 by National Cancer Institute, Naples
Sponsor:
National Cancer Institute, Naples
Collaborator:
Mario Negri Institute for Pharmacological Research
Information provided by (Responsible Party):
National Cancer Institute, Naples
ClinicalTrials.gov Identifier:
NCT01802749
First received: February 27, 2013
Last updated: February 28, 2013
Last verified: February 2013
Meeting Registration: C2D2 BIG QUESTIONS - May 2013: "Grey areas of practitioner ethics: What is changing?"
Blogger's Note: should be an interesting discussion depending on who is involved
| C2D2 BIG QUESTIONS - May 2013: "Grey areas of practitioner ethics: What is changing?" |
Wednesday, May 22, 201312:00 PM - 1:00 PM (Pacific Time)
Show in My Timezone
|
| Welcome to C2D2's Big Questions Webinar series! May's topic is facilitated by Jacquie Dale.
|
The Agenda with Steve Paikin: More or Less Medicine? | Patients' Association of Canada, Association des Patients du Canada
Blogger's Note: not specific to cancer but some general comments (cancer tests vs saving lives/testing); discusses annual checkups; 'overtreatment'; personalized care; more vs better vs less;
The Agenda with Steve Paikin: More or Less Medicine? | Patients' Association of Canada, Association des Patients du Canada
Struck by cancer, killed by ageism - Editorial (eg. age discrimination in cancer care)
Blogger's Note/Opinion: it goes without saying that cancer care safety is the prime concern, however, age biases exist and I suspect that many patients/caregiver are not even aware of age biases in cancer care; over the recent past 60 yrs was deemed 'elderly' with most research now increasing that to 70 yrs (eg. biologic age); the unanswered question - although many are trying, is this: are patients/caregivers informed of all options available as a personalized part of their healthcare?
Struck by cancer, killed by ageism - Editorial - Issues 53 - Articles - Cancer World - Shaping the future of cancer care
"Nearly half the respondents indicated that they had been involved with a cancer patient who had been refused treatment because of their age."
"Discrimination has no place in modern cancer care and determined efforts are required to ensure that age is not a barrier to accessing high-quality diagnosis and treatment."
Thursday, February 28, 2013
Health News - Towards personalised cancer treatment
Health News - Towards personalised cancer treatment
".....“Unfortunately, there are so many different mutations in the tumour cells that clones arise that do not respond to the medication. These clones eventually gain the upper hand and the effect of the medication diminishes over time,” he adds. In some cases second line treatment is available, in others a new mutation profile may reveal more options......
“Unfortunately,
there are so many different mutations in the tumour cells that clones
arise that do not respond to the medication. These clones eventually
gain the upper hand and the effect of the medication diminishes over
time,” he adds. In some cases second line treatment is available, in
others a new mutation profile may reveal more options. - See more at:
http://www.healthcanal.com/cancers/36607-Towards-personalised-cancer-treatment.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+healthnewshc%2FOxfp+%28Health+News+from+HealthCanal.com%29&utm_content=Google+Reader#sthash.1rCgcsZn.dpuf
“Unfortunately,
there are so many different mutations in the tumour cells that clones
arise that do not respond to the medication. These clones eventually
gain the upper hand and the effect of the medication diminishes over
time,” he adds. In some cases second line treatment is available, in
others a new mutation profile may reveal more options. - See more at:
http://www.healthcanal.com/cancers/36607-Towards-personalised-cancer-treatment.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+healthnewshc%2FOxfp+%28Health+News+from+HealthCanal.com%29&utm_content=Google+Reader#sthash.1rCgcsZn.dpuf
“Unfortunately,
there are so many different mutations in the tumour cells that clones
arise that do not respond to the medication. These clones eventually
gain the upper hand and the effect of the medication diminishes over
time,” he adds. In some cases second line treatment is available, in
others a new mutation profile may reveal more options. - See more at:
http://www.healthcanal.com/cancers/36607-Towards-personalised-cancer-treatment.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+healthnewshc%2FOxfp+%28Health+News+from+HealthCanal.com%29&utm_content=Google+Reader#sthash.1rCgcsZn.dpuf
“Unfortunately,
there are so many different mutations in the tumour cells that clones
arise that do not respond to the medication. These clones eventually
gain the upper hand and the effect of the medication diminishes over
time,” he adds. In some cases second line treatment is available, in
others a new mutation profile may reveal more options. - See more at:
http://www.healthcanal.com/cancers/36607-Towards-personalised-cancer-treatment.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+healthnewshc%2FOxfp+%28Health+News+from+HealthCanal.com%29&utm_content=Google+Reader#sthash.1rCgcsZn.dpuf
open/online Feb 2013: Ovarian Cancer - A Clinical and Translational Update | InTechOpen
Ovarian Cancer - A Clinical and Translational Update | InTechOpen
Medicine » Obstetrics and Gynecology
ISBN 978-953-51-1030-9, Hard cover,
371 pages, Publisher: InTech, Published: February 27, 2013 under CC BY 3.0 license
DOI: 10.5772/56234
DOI: 10.5772/56234
"Ovarian Cancer: A Clinical and Translational Update" embraces the most recent advances in diagnosis and treatment of ovarian cancer. With the valuable collaboration of international experts in the field, this book is intended to provide the readership with a comprehensive update in the subject of epithelial ovarian cancer.
- Chapter 1
In what Setting Should Women with Ovarian Cancer Receive Care?
- Chapter 2
- Chapter 3
- Chapter 4
- Chapter 5
- Chapter 6
- Chapter 7
- Chapter 8
- Chapter 9
- Chapter 10
- Chapter 11
- Chapter 12
- Chapter 13
- Chapter 14
- Chapter 15
- Chapter 16
- Chapter 17
Cancers Resist Treatment By "Shuffling Their Genetic Pack"
Blogger's Note: of interest to cancer in general as opposed to a specific cancer
Cancers Resist Treatment By "Shuffling Their Genetic Pack"
"...Swanton says in a statement that by uncovering how cancer cells manage to continually shuffle their genetic pack, it may be possible to turn their strength into a weakness, and create so much instability that the cells can't function normally and die......"
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study : British Journal of Cancer
Abstract : Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study : British Journal of Cancer
Results:
"Age-standardised 3-year net survival was 87–89% in the UK and Denmark, and 91–94% in the other four countries. Stage at diagnosis was relatively advanced in Denmark: only 30% of women had Tumour, Nodes, Metastasis (TNM) stage I disease, compared with 42–45% elsewhere. Women in the UK had low survival for TNM stage III–IV disease compared with other countries."
GPs 'refused access' to ovarian cancer scans | GPonline.com (UK)
GPOnline
"... The charity Target Ovarian Cancer commissioned Ipsos MORI to survey 402 GPs as part of a wider investigation into ovarian cancer care in the UK .......
Included report:
Press Release: (U.S.) Cancer Groups Praise Coverage of Genetic Counseling and Testing Under Affordable Care Act, Urge Coverage of Other Vital Services
Press Release: Cancer Groups Praise Coverage of Genetic Counseling and Testing Under Affordable Care Act, Urge Coverage of Other Vital Services:
Washington, DC—The federal government recently released regulations that clarify which preventive services will be covered under the Affordable Care Act without cost sharing for patients enrolled in private insurance plans. Preventive services are provided without cost sharing to people enrolled in private plans that were established after August 1, 2012. Insurance plans under the Affordable Care Act cannot apply a co-pay or deductible to services outlined in the act.
Among the services included in these regulations are genetic counseling and testing for inherited breast and ovarian cancer risk in women with a family history of cancer. Breast and ovarian cancers have been linked to mutations in the BRCA1 and BRCA2 genes.
The Ovarian Cancer National Alliance, FORCE, Bright Pink and CCARE Lynch Syndrome applaud the government’s attention to women’s health services in general and preventive services in particular. We are happy that genetic counseling and genetic testing will be covered without cost-sharing, as these are important services for women who may have an increased risk of ovarian and breast cancers. The new regulations are a step in the right direction, but they have only taken us halfway there. We are concerned that the current regulations do not include the following:
- genetic counseling or testing in people with a family history indicative of Lynch Syndrome (which is associated with colon, uterine, and ovarian cancer) or other hereditary cancer syndromes;
paywalled: Safety and feasibility of targeted agent combinations in solid tumours : Nature Reviews Clinical Oncology
Abstract
"The
plethora of novel molecular-targeted agents (MTAs) has provided an
opportunity to selectively target pathways involved in carcinogenesis
and tumour progression. Combination strategies of MTAs are being used to
inhibit multiple aberrant pathways in the hope of optimizing antitumour
efficacy and to prevent development of resistance. While the selection
of specific agents in a given combination has been based on biological
considerations (including the role of the putative targets in cancer)
and the interactions of the agents used in combination, there has been
little exploration of the possible enhanced toxicity of combinations
resulting from alterations in multiple signalling pathways in normal
cell biology. Owing to the complex networks and crosstalk that govern
normal and tumour cell proliferation, inhibiting multiple pathways with
MTA combinations can result in unpredictable disturbances in normal
physiology. This Review focuses on the main toxicities and the lack of
tolerability of some common MTA combinations, particularly where
evidence of enhanced toxicity compared to either agent alone is
documented or there is development of unexpected toxicity. Toxicities
caused by MTA combinations highlight the need to introduce new
preclinical testing paradigms early in the drug development process for
the assessment of chronic toxicities resulting from such combinations."
(ovarian cancer/Dr Oz) Reality Check: There is No Such Thing as a Miracle Food
Abstract:
"A
recent episode of the Dr. Oz Show suggested endive, red onion, and sea
bass as foods that can decrease the risk of ovarian cancer by up to 75%.
However, the scientific evidence supporting these recommendations is
limited. This commentary discusses some of the concerns related to the
promotion of “miracle foods” by the media. Nutritional scientists and
epidemiologists should be cognizant of the public health messages that
are taken from their individual studies and not sensationalize the
findings of a single study."
BMC Cancer-open access: Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case--control study
Abstract Results and Conclusions:
Results
We did not find evidence of an association between consumption of sugary foods and
beverages and risk, although there was a suggestion of increased risk associated with
sugary drink intake (servings per 1,000 kcal; OR=1.63, 95% CI: 0.94-2.83).
Conclusions
Overall, we found little indication that sugar intake played a major role on ovarian
cancer development.
Conclusions
To our knowledge this is the first study to evaluate ovarian cancer risk in relation to total and individual consumption of sugary foods and beverages, total and added sugar intake, as well as a potential effect modification by several insulin-related risk factors. Although in our study there was a suggestion of a moderately increased cancer risk associated with sugary beverage consumption, overall, we did not detect significant relationships with any of the sugar variables evaluated. The overall evidence for sugary foods and drinks and added sugars remains inconclusive. These apparent gaps in the literature emphasize the need for future research, preferably large prospective studies, to evaluate the role of added sugars in the etiology of ovarian cancer, while taking into consideration various factors capable of influencing the body’s insulin response such as anthropometric measures and physical activity.
American Journal of Gastroenterology - Direct Visualization of an Extremely Rare Malignancy: Adenocarcinoma of the Appendix
Blogger's Note: I have not updated myself recently on this particular issue (carcinoma of the appendix), however, several years ago there was a clinical trial (clinicaltrials.gov) specific to adenocarcinoma of the appendix; patients with a known genetic condition (eg. Lynch Syndrome) were excluded from participating; opinion (mine): given the rarity of the condition it may have been 'wiser' to include all participants so affected; aside from known genetic predispositions it 'seems' there may be a familiar aspect to carcinoma of the appendix
American Journal of Gastroenterology - Direct Visualization of an Extremely Rare Malignancy: Adenocarcinoma of the Appendix
Subscribe to:
Posts
(
Atom
)
